Aptamer conjugated polydopamine-coated gold nanoparticles as a dual-action nanoplatform targeting β-amyloid peptide for Alzheimer's disease therapy.
Juan QinYanxue GuanZongjia LiXinyue GuoMiaomiao ZhangDapeng WangJilin TangPublished in: Journal of materials chemistry. B (2022)
The accumulation and deposits of amyloid beta (Aβ) peptide are an important pathological hallmark of Alzheimer's disease (AD). The development of multifunctional agents that can effectively clear Aβ aggregates is one of the potential strategies to treat AD. Herein, aptamer conjugated polydopamine-coated gold nanoparticles (Au@PDA-Apt NPs) for targeting Aβ 1-40 peptides were designed. Au@PDA-Apt NPs exhibited a strong capability to inhibit Aβ 1-40 monomer fibrillization and disaggregate mature Aβ 1-40 fibrils. In addition, Au@PDA-Apt NPs could effectively alleviate Aβ 1-40 -triggered cytotoxicity. Importantly, AFM quantitative nanomechanical measurements indicated that Au@PDA-Apt NPs could prevent cell membrane damage and decrease of cell mechanical properties caused by Aβ 1-40 aggregation. Taken together, this study provided a new dual-action nanoplatform for Aβ-targeted AD therapy.
Keyphrases
- gold nanoparticles
- reduced graphene oxide
- cancer therapy
- sensitive detection
- photodynamic therapy
- drug delivery
- oxide nanoparticles
- magnetic nanoparticles
- quantum dots
- atomic force microscopy
- cognitive decline
- cell therapy
- single cell
- oxidative stress
- high resolution
- high speed
- drug release
- climate change
- mild cognitive impairment
- molecularly imprinted
- single molecule
- replacement therapy